1,009,136 Merck & Co., Inc. $MRK Shares Purchased by State Street Corp

State Street Corp increased its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 0.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 121,422,392 shares of the company’s stock after buying an additional 1,009,136 shares during the quarter. State Street Corp’s holdings in Merck & Co., Inc. were worth $17,745,131,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Round Rock Advisors LLC grew its position in Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after purchasing an additional 66 shares in the last quarter. Cypress Wealth Services LLC lifted its position in Merck & Co., Inc. by 0.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after buying an additional 69 shares in the last quarter. Code Waechter LLC lifted its position in Merck & Co., Inc. by 3.4% during the 3rd quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after buying an additional 71 shares in the last quarter. Quest 10 Wealth Builders Inc. lifted its position in Merck & Co., Inc. by 12.2% during the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock worth $102,000 after buying an additional 76 shares in the last quarter. Finally, Cascade Financial Partners LLC boosted its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after buying an additional 80 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MRK shares. Jefferies Financial Group raised their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a report on Wednesday, August 12th. Wolfe Research increased their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Citigroup increased their price target on Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, October 12th. Finally, Sanford C. Bernstein raised their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $155.74.

Read Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $133.56 on Friday. The stock has a market cap of $329.26 billion, a P/E ratio of 137.69, a P/E/G ratio of 6.62 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The company has a fifty day moving average price of $145.28 and a two-hundred day moving average price of $129.29. Merck & Co., Inc. has a one year low of $95.36 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.58 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current year.

Merck & Co., Inc. Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.88 per share. The ex-dividend date is Tuesday, December 15th. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. This represents a $3.52 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is 350.52%.

Key Merck & Co., Inc. News

Investors following MRK have been watching these news items:

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president owned 112,955 shares of the company’s stock, valued at $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.